FibroGen Inc (FGEN)
0.3699
+0.04
(+11.89%)
USD |
NASDAQ |
Nov 14, 16:00
0.38
+0.01
(+2.73%)
After-Hours: 20:00
FibroGen Research and Development Expense (Quarterly): 34.11M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 34.11M |
| March 31, 2024 | 38.39M |
| December 31, 2023 | 51.70M |
| September 30, 2023 | 61.19M |
| June 30, 2023 | 95.48M |
| March 31, 2023 | 74.49M |
| December 31, 2022 | 61.63M |
| September 30, 2022 | 75.18M |
| June 30, 2022 | 70.96M |
| March 31, 2022 | 89.02M |
| December 31, 2021 | 113.92M |
| September 30, 2021 | 75.88M |
| June 30, 2021 | 122.57M |
| March 31, 2021 | 74.68M |
| December 31, 2020 | 78.13M |
| September 30, 2020 | 58.48M |
| June 30, 2020 | 61.41M |
| March 31, 2020 | 54.90M |
| December 31, 2019 | 56.80M |
| September 30, 2019 | 49.96M |
| June 30, 2019 | 52.01M |
| March 31, 2019 | 50.50M |
| Date | Value |
|---|---|
| December 31, 2018 | 70.28M |
| September 30, 2018 | 56.44M |
| June 30, 2018 | 52.14M |
| March 31, 2018 | 56.97M |
| December 31, 2017 | 52.47M |
| September 30, 2017 | 50.34M |
| June 30, 2017 | 46.98M |
| March 31, 2017 | 46.73M |
| December 31, 2016 | 50.61M |
| September 30, 2016 | 40.56M |
| June 30, 2016 | 52.39M |
| March 31, 2016 | 43.65M |
| December 31, 2015 | 59.92M |
| September 30, 2015 | 52.07M |
| June 30, 2015 | 51.56M |
| March 31, 2015 | 50.54M |
| December 31, 2014 | 51.26M |
| September 30, 2014 | 40.62M |
| June 30, 2014 | 33.27M |
| March 31, 2014 | 25.65M |
| December 31, 2013 | 29.43M |
| September 30, 2013 | 23.18M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
34.11M
Minimum
Jun 2024
122.57M
Maximum
Jun 2021
71.00M
Average
70.96M
Median
Jun 2022
Research and Development Expense (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 184.90M |
| Arbutus Biopharma Corp | 14.27M |
| GlycoMimetics Inc | 6.286M |
| Cidara Therapeutics Inc | 12.43M |
| Cue Biopharma Inc | 9.53M |